
|Podcasts|April 26, 2018
Significant Improvement Found in Clinical Trial for Dravet Syndrome
Author(s)Andrew N. Wilner, MD
An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.
Advertisement
Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.
In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.
If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.
RELATED CONTENT:
More podcasts
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date
4
Contextualizing Lecanemab’s New Subcutaneous Weekly Starting Dose
5
















